|
Today's Headlines
An Endocrine Society task force has established new clinical-practice guidelines that recommend screening adults for high triglyceride levels once every 5 years because of the potential risk of cardiovascular disease and pancreatitis associated with hypertriglyceridemia. » Full article
|
|
FDA has approved aflibercept (Eylea, Regeneron) injection for the treatment of macular edema following central retinal vein occlusion. The recommended dose for Eylea is 2 mg every 4 weeks (monthly). » Full article
|
|
Tight glycemic control can be achieved in children following cardiac surgery, but it does not reduce the infection rate, mortality, or length of hospital stay compared to standard care, according to a study published in the September 7 issue of The New England Journal of Medicine. » Full article
|
|
The long-term use of gingko biloba extract does not lower the risk of Alzheimer's disease, according to a report published September 6 online for The Lancet. » Full article
|
|
CONTINUING EDUCATION
Welcome to a new CPE series: Medication Therapy Management (MTM) in Patients with Diabetes, which has been designed for pharmacists who take care of patients with diabetes. You can earn up to 14 CPE credits from September 2012-March 2013 with 7 monthly knowledge-based activities. This month, the professional development activity will cover the pathophysiology, diagnosis, screening, and risk factors associated with diabetes mellitus.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.
|
|
EDITOR'S PICK
Teduglutide is a recombinant analog of human glucagon-like peptide-2 that is awaiting FDA approval for the treatment of short bowel syndrome (SBS) as a once-daily subcutaneous injection. Teduglutide represents a major improvement in the treatment of SBS given that existing therapies are limited. » Full article
|
Survey
a) Further broaden the gap between copay dollar value between preferred and non-preferred brand drug tiers.
b) Demand increase formulary rebates requested from manufacturers of preferred products.
c) Implement more aggressive utilization management (PA, Step, Therapeutic Interchange, etc.) to specifically target these products.
d) Enhanced employment of a closed-formulary benefit design.
e) No action, as I don't believe this couponing will have significant effects.
Respond here and see what your colleagues think too.Want to see the results of our last survey regarding preventive services legislation? Click here.
|
|
|
Like
Tweet
